Results from the IMpassion132 trial presented at ESMO Breast 24

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“Results from the IMpassion132 trial presented at ESMO Breast 24 reveal that adding atezolizumab to chemotherapy does not improve overall survival in patients with advanced triple-negative breast cancer (TNBC) relapsing within 12 months after initial treatment.
However, according to Carmen Criscitiello, the higher objective response rate achieved with atezolizumab suggests that at least some patients could benefit from it, and this highlights the importance of individualised treatment approaches.

Read more in the ESMO Daily Reporter article.”

Source: ESMO/LinkedIn
OncoDaily